Novo Nordisk, Eli Lilly Slip as Roche Weight-Loss Drug Shows Promise

Roche announced strong early stage data from its weight-loss drug CT-996. The once-daily pill delivered placebo-adjusted mean weight loss of 6.1% in obesity patients without diabetes. CT-996 represent possible competition to popular weight-loss drugs Novo Nordisk's Wegovy and Eli Lilly's Zepbound. Roche Added Drug To Pipeline With Carmot Therapeutics Acquisition tips@investopedia.com A new non-injectable weight-loss drug from Swiss pharmaceutical firm Roche Holding AG has shown encouraging early stage data, ...